Single Strain

MF1298

JUMP TO:
01
Summary

One study has assessed the effectiveness of Lactobacillus plantarum MF1298 in relieving symptoms of irritable bowel syndrome (IBS).(1) Conducted as a randomized double-blind placebo-controlled crossover trial, this study involved 16 IBS subjects who underwent two three-week periods of daily intake of either L. plantarum MF 1298 or placebo, separated by a four-week washout period.

The probiotic dose was 10 billion CFU per day. Results indicated that a significant majority (81%) of participants preferred the placebo over the probiotic. Additionally, the number of weeks with satisfactory symptom relief and the IBS sum score were both notably lower during the period of L. plantarum MF1298 treatment compared to the placebo period. This suggests that L. plantarum MF1298 worsened IBS symptoms, and this effect was notable for the symptoms of diarrhea, abdominal pain, and global IBS symptoms. 

Key Takeaway

At this time, evidence suggests that Lactobacillus plantarum MF1298 may worsen IBS symptoms.  

Dosing Instructions

  • None 

References:

  1. Ligaarden, S.C., Axelsson, L., Naterstad, K. et al. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol 10, 16 (2010). 
Read More…

One study has assessed the effectiveness of Lactobacillus plantarum MF1298 in relieving symptoms of irritable bowel syndrome (IBS).(1) Conducted as a randomized double-blind placebo-controlled crossover trial, this study involved 16 IBS subjects who underwent two three-week periods of daily intake of either L. plantarum MF 1298 or placebo, separated by a four-week washout period.

The probiotic dose was 10 billion CFU per day. Results indicated that a significant majority (81%) of participants preferred the placebo over the probiotic. Additionally, the number of weeks with satisfactory symptom relief and the IBS sum score were both notably lower during the period of L. plantarum MF1298 treatment compared to the placebo period. This suggests that L. plantarum MF1298 worsened IBS symptoms, and this effect was notable for the symptoms of diarrhea, abdominal pain, and global IBS symptoms. 

Key Takeaway

At this time, evidence suggests that Lactobacillus plantarum MF1298 may worsen IBS symptoms.  

Dosing Instructions

  • None 

References:

  1. Ligaarden, S.C., Axelsson, L., Naterstad, K. et al. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol 10, 16 (2010). 
Read More…
Find a probiotic with MF1298

There is insufficient evidence demonstrating benefits for IBS with this probiotic. Therefore, we do not provide guidance on finding a commercial product containing this strain/blend.

One study has assessed the effectiveness of Lactobacillus plantarum MF1298 in relieving symptoms of irritable bowel syndrome (IBS).(1) Conducted as a randomized double-blind placebo-controlled crossover trial, this study involved 16 IBS subjects who underwent two three-week periods of daily intake of either L. plantarum MF 1298 or placebo, separated by a four-week washout period.

The probiotic dose was 10 billion CFU per day. Results indicated that a significant majority (81%) of participants preferred the placebo over the probiotic. Additionally, the number of weeks with satisfactory symptom relief and the IBS sum score were both notably lower during the period of L. plantarum MF1298 treatment compared to the placebo period. This suggests that L. plantarum MF1298 worsened IBS symptoms, and this effect was notable for the symptoms of diarrhea, abdominal pain, and global IBS symptoms. 

Key Takeaway

At this time, evidence suggests that Lactobacillus plantarum MF1298 may worsen IBS symptoms.  

Dosing Instructions

  • None 

References:

  1. Ligaarden, S.C., Axelsson, L., Naterstad, K. et al. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol 10, 16 (2010). 
02
Results
Overall evidence quality grade
67%

This probiotic has low to moderate quality studies in IBS populations supporting it. View our evidence evaluation framework to learn how we assess the quality of studies.

Refine by Probiotic(s) In this view, show results

Close
  • Where trash
    trash

Add condition

03
Patient Handout
Share
04
Clinical Studies
  • #
  • Study
  • Year
  • Author(s)
  • Journal
  • Reference
  • Daily Dose
  • Duration of Intervention
  • Form
  • Study Design
  • Age
  • Participants
    • Study #1

    • A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial

    • 2010
    • Ligaarden, S.C., Axelsson, L., Naterstad, K. et al.

    • BMC Gastroenterol 10, 16 (2010)

    • DOI: 10.1186/1471-230X-10-16. PMID: 20144246; PMCID: PMC2831047.
    • 10 billion CFU
    • 2 3-week intervention periods
      separated by a 4 week washout period
    • Capsule
      • RANDOMIZED
      • DOUBLE-BLIND
      • PLACEBO-CONTROLLED
      • CROSSOVER

    • ADULTS     18-75 years

    • ITT,PP (total) n=19,16
05
Findings from studies

#

  • Diarrhea
  • Constipation
  • Bowel Habits
  • Global IBS Symptoms
  • Abdominal Pain / Discomfort
  • Bloating / Distention
  • Gas / Flatulence
  • Nausea / Vomiting
  • Mental Health
  • Quality of Life
  • Miscellaneous Symptoms
  • Notes

  • Study #1

    • Diarrhea

      • The IBS sum score and the score for diarrhea were significantly higher in the period of L. plantarum MF1298 treatment than with placebo.

      • There was a statistically significant difference between the placebo and probiotic intervention periods for urgency (p=0.002) with the probiotic producing a worsened symptom profile.

    • Constipation

      • There was no statistically significant difference between the placebo and probiotic intervention periods for straining (p=0.13)

    • Bowel Habits

      • There was no statistically significant difference between the placebo and probiotic intervention periods for normalized stool frequency or consistency.

    • Global IBS Symptoms

      • Thirteen participants (81%; CI 57% to 93%; P = 0.012) preferred placebo to L. plantarum MF1298 treatment. The number of weeks with satisfactory relief of symptoms was statistically significantly higher in the placebo period compared with the L. plantarum MF1298 period.

      • The IBS sum score in the active period was 6.44 (1.81), in the placebo period 5.35 (1.77), and the correlation between these was 0.66. The difference in IBS sum score between active treatment and placebo was 1.09 (1.47).

      • The resulting proportion of subjects with a score difference of at least 2 in disfavour of active treatment was 27% (CI 9% to 44%), and the number needed to harm was 3.7 (CI 2.3 to 10.9).

    • Abdominal Pain / Discomfort

      • For abdominal pain, there was a statistically significant difference between the probiotic and placebo intervention with worsened scores occurring during the probiotic intervention (p=0.016)

    • Bloating / Distention

      • There was no statistically significant difference between the probiotic and placebo for bloating (p=0.69)

    • Gas / Flatulence

      • No data

    • Nausea / Vomiting

      • No data

    • Mental Health

      • No data

    • Quality of Life

      • No data

    • Miscellaneous Symptoms

      • No data

    • Notes

      • No data